Literature DB >> 2606472

G2 chromosomal radiosensitivity in families with ataxia-telangiectasia.

Y Shiloh1, R Parshad, M Frydman, K K Sanford, S Portnoi, Y Ziv, G M Jones.   

Abstract

Ataxia-telangiectasia (A-T) is an autosomal recessive disease involving chromosomal instability, susceptibility to cancer and X-ray hypersensitivity. The latter two features are expressed to a limited extent in the heterozygous carriers of A-T mutations. Although fibroblast lines from A-T heterozygotes clearly show increased susceptibility to the lethal effect of X-irradiation, the difference in post-irradiation survival between cell lines and normal controls is not always large enough to allow the use of X-ray sensitivity as a laboratory assay for carrier detection in A-T. Recently, we have shown in a blind study, that the extent of chromatid damage induced in the G2 phase of the cell cycle by moderate doses of X-rays is markedly higher in A-T heterozygous cells than in normal controls. We have now applied this test to 6 additional obligatory heterozygotes and 24 individuals with different risks of being A-T carriers, from three Israeli A-T families. All 6 cell lines from the obligatory heterozygotes showed the typical hypersensitivity to the clastogenic action of X-rays in G2; of the 24 cell lines with unknown A-T genotype, 16 showed the same hypersensitivity, and 8 responded in a normal way. The proportion of cell lines showing the "A-T-heterozygous phenotype" was in accord with the expected value, based on Mendelian chance calculations. Since these observations were made, a daughter of two hypersensitive parents in one of these families has been diagnosed as having A-T. This confirmed the presumed A-T heterozygosity of the parents, as indicated by the laboratory assay.

Entities:  

Mesh:

Year:  1989        PMID: 2606472     DOI: 10.1007/bf00210663

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  28 in total

1.  Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain.

Authors:  E C Pippard; A J Hall; D J Barker; B A Bridges
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

2.  Fluorescent light-induced DNA crosslinkage and chromatid breaks in mouse cells in culture.

Authors:  R Gantt; R Parshad; R A Ewig; K K Sanford; G M Jones; R E Tarone; K W Kohn
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

3.  Carrier detection in ataxia-telangiectasia.

Authors:  Y Shiloh; R Parshad; K K Sanford; G M Jones
Journal:  Lancet       Date:  1986-03-22       Impact factor: 79.321

4.  Attempts to detect ataxia telangiectasia (AT) heterozygotes by cytogenetical techniques.

Authors:  A T Natarajan; M Meijers; A A van Zeeland; J W Simons
Journal:  Cytogenet Cell Genet       Date:  1982

5.  Malignant neoplasms in the families of patients with ataxia-telangiectasia.

Authors:  M Swift; L Sholman; M Perry; C Chase
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

6.  Abnormal response of ataxia-telangiectasia cells to agents that break the deoxyribose moiety of DNA via a targeted free radical mechanism.

Authors:  Y Shiloh; E Tabor; Y Becker
Journal:  Carcinogenesis       Date:  1983-10       Impact factor: 4.944

7.  In vitro phenotype of ataxia-telangiectasia (AT) fibroblast strains: clues to the nature of the "AT DNA lesion" and the molecular defect in AT.

Authors:  Y Shiloh; E Tabor; Y Becker
Journal:  Kroc Found Ser       Date:  1985

8.  Chromosomal radiosensitivity during the G2 cell-cycle period of skin fibroblasts from individuals with familial cancer.

Authors:  R Parshad; K K Sanford; G M Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

9.  Breast and other cancers in families with ataxia-telangiectasia.

Authors:  M Swift; P J Reitnauer; D Morrell; C L Chase
Journal:  N Engl J Med       Date:  1987-05-21       Impact factor: 91.245

10.  G2 chromosomal radiosensitivity of ataxia-telangiectasia heterozygotes.

Authors:  R Parshad; K K Sanford; G M Jones; R E Tarone
Journal:  Cancer Genet Cytogenet       Date:  1985-01-01
View more
  7 in total

1.  Heterogeneity in the clastogenic response to X-rays in lymphocytes from ataxia-telangiectasia heterozygotes and controls.

Authors:  J K Wiencke; D W Wara; J B Little; K T Kelsey
Journal:  Cancer Causes Control       Date:  1992-05       Impact factor: 2.506

2.  Examination of Genetic Susceptibility in Radiation-Associated Meningioma.

Authors:  A Pemov; J Kim; K Jones; A Vogt; S Sadetzki; D R Stewart
Journal:  Radiat Res       Date:  2022-07-01       Impact factor: 3.372

3.  Complementation of a DNA repair deficiency in six human tumor cell lines by chromosome 11.

Authors:  R Parshad; F M Price; M Oshimura; J C Barrett; H Satoh; B E Weissman; E J Stanbridge; K K Sanford
Journal:  Hum Genet       Date:  1992-03       Impact factor: 4.132

Review 4.  Enhanced risks of cancer from protracted exposures to X- or gamma-rays: a radiobiological model of radiation-induced breast cancer.

Authors:  M M Elkind
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

5.  Cellular responses to ionising radiation of AT heterozygotes: differences between missense and truncating mutation carriers.

Authors:  M Fernet; N Moullan; A Lauge; D Stoppa-Lyonnet; J Hall
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

Review 6.  Ataxia telangiectasia: a review.

Authors:  Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman
Journal:  Orphanet J Rare Dis       Date:  2016-11-25       Impact factor: 4.123

7.  Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence.

Authors:  Hege Edvardsen; Toril Tefre; Laila Jansen; Phuong Vu; Bruce G Haffty; Sophie D Fosså; Vessela N Kristensen; Anne-Lise Børresen-Dale
Journal:  Radiat Oncol       Date:  2007-07-10       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.